TCRR News

Levi Strauss (LEVI) is bringing its blue jeans back to public markets. This week the company filed for an IPO that we estimate could raise $750 million, coming as early as March. It's no wonder Levi is going public, based on its 2017 and 2018 financials, which saw sales growth of 8% and 14%, respectively. That's especially impressive given the current...read more

TCR2 Therapeutics, a early stage biotech developing immunotherapies for various cancers, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. TCR2 Therapeutics plans to list on the Nasdaq under the symbol TCRR. Jefferies, SVB Leerink and BMO Capital Markets acted as lead managers on the deal....read more

Railroad IPOs were hot in the 1850's, but two billionaires are bringing the industry back this week with an offering of Virgin Trains USA. In total, the week could see up to seven deals, but Virgin Trains USA's $510 million IPO is larger than the other six combined. These others are mostly small healthcare IPOs: ...read more

TCR2 Therapeutics, an early-stage biotech developing T cell immunotherapies for various cancers, announced terms for its IPO on Friday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, TCR2...read more